Commentary: "Healthcare Professionals' Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease" by Dankers M et al. in Frontiers in Pharmacology 2020; 10: 1519 - Harma Alma; Harma Alma; Corina de Jong; Corina de Jong; Janwillem Kocks; Janwillem Kocks; Janwillem Kocks; Thys van der Molen; Thys van der Molen (Frontiers Media S.A., 2020)